Only in Titles

Search results for: Androgen

paperclip

#34706118   2021/10/27 To Up

Prostatic fluid composition and semen quality in dogs with benign prostatic hyperplasia undergoing treatment with osaterone acetate.

Benign prostatic hyperplasia (BPH) may alter prostatic fluid biochemical composition causing reduced fertility. Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH. Little information exists on effects of OA administration on biochemical composition of canine prostatic fluid and its role on fertility. The aim of this research was to study biochemical composition of prostatic fluid and its role on semen quality in dogs with BPH undergoing treatment with OA. Eight intact, 5-11-year-old dogs with benign prostatic hyperplasia were treated orally with OA at a dose of 0.25-0.5 mg/Kg once daily for seven days. Prostatic volume, semen evaluation and a biochemical analysis of prostatic fluid were performed on the day before treatment (D0), D60, D120, D180 and D240. A significant reductionof prostatic volume was observed at D60 and D120, respectively, and a significant reduction (20%) of normal spermatozoa was observed at D60 coincident with a significant increase of sperm tail defects, which disappeared during the course of the treatment. Prostatic fluid composition did not vary during the OA treatment except for zinc (Zn ) with a significant increase at D120 and D180 correlated with the return to normal sperm values. In conclusion, canine Zn prostatic fluid concentrations decrease during development of BPH and return to normal during treatment with OA. Zn is an important electrolyte for semen quality, suggesting that oral Zn supplementation might be considered as a treatment to improve semen quality.
Lluis Ferré-Dolcet, Lisa Frigotto, Barbara Contiero, Silvia Bedin, Stefano Romagnoli

1674 related Products with: Prostatic fluid composition and semen quality in dogs with benign prostatic hyperplasia undergoing treatment with osaterone acetate.

100 μg100 μg0.5 mg10 mg10 mg25 mg

Related Pathways

paperclip

#34705446   2021/10/27 To Up

Using High-Throughput Screening to Evaluate Perturbations Potentially Linked to Neurobehavioral Outcomes: A Case Study Using Publicly Available Tools on FDA Batch-Certified Synthetic Food Dyes.

There is growing evidence from human and animal studies indicating an association between exposure to synthetic food dyes and adverse neurobehavioral outcomes in children. However, data gaps persist for potential mechanisms by which the synthetic food dyes could elicit neurobehavioral impacts. We developed an approach to evaluate seven US FDA-batch-certified food dyes using publicly available high-throughput screening (HTS) data from the US EPA's Toxicity Forecaster to assess potential underlying molecular mechanisms that may be linked to neurological pathway perturbations. The dyes were screened through 270 assays identified based on whether they had a neurological-related gene target and/or were mapped to neurodevelopmental processes or neurobehavioral outcomes, and were conducted in brain tissue, targeted specific hormone receptors, or targeted oxidative stress and inflammation. Some results provided support for neurological impacts found in human and animal studies, while other results showed a lack of correlation with findings. The azo dyes had a range of activity in assays mapped to G-protein-coupled receptors and were active in assays targeting dopaminergic, serotonergic, and opioid receptors. Assays mapped to nuclear receptors (androgen, estrogen, and thyroid hormone) also exhibited activity with the food dyes. Other molecular targets included the aryl hydrocarbon receptor, acetylcholinesterase, and monoamine oxidase. The Toxicological Prioritization Index tool was used to visualize the results of the Novascreen assays. Our results highlight certain limitations of HTS assays but provide insight into potential underlying mechanisms of neurobehavioral effects observed in animal toxicology studies and human clinical studies.
Nathalie Pham, Mark D Miller, Melanie Marty

2905 related Products with: Using High-Throughput Screening to Evaluate Perturbations Potentially Linked to Neurobehavioral Outcomes: A Case Study Using Publicly Available Tools on FDA Batch-Certified Synthetic Food Dyes.

1 module0.1 mg1 module

Related Pathways

paperclip

#34705329   2021/10/27 To Up

HepG2 as promising cell-based model for biosynthesis of long-term metabolites - exemplified for metandienone.

In order to detect the abuse of substances in sports, the knowledge of their metabolism is of undisputable importance. As in vivo administration of compounds faces ethical problems and might even not be applicable for non-approved compounds, cell-based models might be a versatile tool for biotransformation studies. We co-incubated HepG2 cells with metandienone and D -epitestosterone for 14 days. Phase I and II metabolites were analyzed by HPLC-tandem mass spectrometry, and confirmed by GC-MS. The metandienone metabolites formed by HepG2 cells were comparable to those renally excreted by humans. HepG2 cells also generated the two long-term metabolites 17β-hydroxymethyl-17α-methyl-18-nor-androst-1,4,13-trien-3-one and 17α-hydroxymethyl-17β-methyl-18-nor-androst-1,4,13-trien-3-one used in doping analyses, though in an inverse ratio compared to that observed in human urine. In conclusion, we showed that HepG2 cells are suitable as model for the investigation of biotransformation of androgens, especially for the anabolic androgenic steroid metandienone. They further proved to cover phase I and II metabolic pathways, which combined with a prolonged incubation time with metandienone resulted in the generation of its respective long-term metabolites known from in vivo metabolism. Moreover, we showed the usability of D -epitestosterone as internal standard for the incubation. The method used herein appears to be suitable and advantageous compared to other models for the investigation of doping-relevant compounds, probably enabling the discovery of candidate metabolites for doping analyses.
Annette Zschiesche, Zdenek Chundela, Detlef Thieme, Annekathrin M Keiler

2216 related Products with: HepG2 as promising cell-based model for biosynthesis of long-term metabolites - exemplified for metandienone.

100 assays100μg100ug100tests25 μg100μg1,000 tests96 Tests

Related Pathways

paperclip

#34704930   // To Up

[Cardiac arrest in a patient with long QT syndrome receiving androgen deprivation therapy].

This is a case report of a 72-year-old male with a newly diagnosed prostate cancer, who was treated with androgen deprivation therapy and anti-androgen. The patient was diagnosed with congenital long QT syndrome (LQTS), and a markedly worsening of the QT-prolongation was observed, after the hormonal therapy was initiated. He ultimately suffered an initially resuscitated cardiac arrest but did not survive to discharge. Pharmaceutical treatments in patients with LQTS should always be handled with caution, and if a treatment with a known or probable QT-prolonging drug is initiated, a cardiologist should be consulted.
Niels Kjær Stampe, Jacob Tfelt-Hansen, Bo Gregers Winkel, Alessandro Venzo

2356 related Products with: [Cardiac arrest in a patient with long QT syndrome receiving androgen deprivation therapy].

100 μg100 μg15100ug20 ul (10 mM)100 μg100 μg100 μg

Related Pathways

paperclip

#34704159   2021/10/26 To Up

Sexual Function After Voluntary Castration.

Some genetic males undergo voluntary castration, with and without hormonal supplementation. Here, we investigate the sexual function of 163 such individuals (average age = 52 ± 16-years-old). Specifically, we explored how hormonal, social, and psychological factors play a role in their sexual function. In this study, 47% identified their gender as "eunuch", and 36% identified their gender as "man." Furthermore, 64% were in a relationship (80% with a woman), and 28% had a strong attraction for both sexes (Kinsey 2-4). We found that castrated individuals with androgen supplementation have higher sexual function than those without any hormone supplementation. Individuals with anxiety symptoms reported better sexual parameters (better orgasm satisfaction, easier to achieve an erection and an orgasm) than those without anxiety symptoms. Among those low in anxiety, individuals without hormone supplementation had a weaker sex drive and more difficulty in getting sexually aroused than those on supplemental estrogen or androgen. Hierarchical multiple regressions indicated that control variables (i.e., age, depressive symptoms, time since castration, type of hormone supplementation) accounted for 13-30% of the variances in sexual parameters. Including sexual guilt in the models predicted 4-8% additional variances in all sexual parameters except for ease in getting and maintaining an erection. Adding in participants' sexual trauma scores accounted for an additional 3.7% in the strength of their reported sex drive. In conclusion, various factors-hormone therapy, anxiety, sexual guilt, and childhood trauma-may influence the sexual outcomes for castrated individuals.
Erik Wibowo, Samantha T S Wong, Richard J Wassersug, Thomas W Johnson

2099 related Products with: Sexual Function After Voluntary Castration.

200.00 ug1200.00 ug1 kit(96 Wells)200.00 ug1 kit(96 Wells)100.00 ug100 mg200.00 ug1 kit(96 Wells)200.00 ug1 kit(96 Wells)

Related Pathways

paperclip

#34703954   2021/09/10 To Up

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer.

Treatment with long-term androgen deprivation therapy (ADT) and radiation therapy (RT) is the nonsurgical standard-of-care for patients with high- or very high-risk prostate cancer (HR-PC), but the optimal timing between ADT and RT initiation is unknown. We evaluate the influence of timing between ADT and RT on outcomes in patients with HR-PC using a large national cancer database.
Neal S McCall, Yuan Liu, Sagar A Patel, Bruce Hershatter, Drew Moghanaki, Karen D Godette, Sheela Hanasoge, Pretesh Patel, Benjamin W Fischer-Valuck, Joseph W Shelton, Ashesh B Jani

2447 related Products with: Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer.

25

Related Pathways

paperclip

#34703906   2021/10/12 To Up

KLF9 suppresses cell growth and induces apoptosis via the AR pathway in androgen-dependent prostate cancer cells.

Kruppel-like factors (KLFs) play an important role in many biological processes including cell proliferation, differentiation and development. Our study showed that the level of KLF9 is lower in PCa cell lines compared to a benign prostate cell line; the androgen-independent cell line PC3 expresses significantly lower KLF9 than the androgen-dependent cell line, LNCaP. Forced overexpression of KLF9 suppressed cell growth, colony formation, and induced cell apoptosis in LNCaP cells. We also found that KLF9 expression was induced in response to apoptosis caused by flutamide, and further addition of dihydrotestosterone antagonized the action of flutamide and significantly decreased KLF9 expression. Furthermore, activation of the androgen receptor (AR) was inhibited by the overexpression of KLF9. Our research shows that KLF9 is lower in androgen-independent cell lines than in androgen-dependent cell lines; Overexpression of KLF9 dramatically suppresses the proliferation, anchorage-independent growth, and induces apoptosis in androgen-dependent cells; KLF9 inhibition on prostate cancer cell growth may be acting through the AR pathway. Our results therefore suggest that KLF9 may play a significant role in the transition from androgen-dependent to androgen-independent prostate cancer and is a potential target of prevention and therapy.
Pengliang Shen, Xiaoming Cao, Libin Sun, Yu Qian, Bo Wu, Xin Wang, Guowei Shi, Dongwen Wang

2615 related Products with: KLF9 suppresses cell growth and induces apoptosis via the AR pathway in androgen-dependent prostate cancer cells.

2 Pieces/Box2 Pieces/Box2 Pieces/Box

Related Pathways

paperclip

#34703592   2021/10/14 To Up

Case report: A rare occurrence of a huge mediastinal mass from disseminated prostate carcinoma.

Prostatic carcinoma is the commonest malignancy among men. It usually metastasizes to the spine and regional lymph nodes. However, it is extremely rare for it to metastasize to the mediastinum.
Kai Ming Teah, Ching Pei Bong, Kamarudin Mudin, May Zaw Soe, Shankaran Thevarajah, Boon Tat Yeap

2117 related Products with: Case report: A rare occurrence of a huge mediastinal mass from disseminated prostate carcinoma.



Related Pathways

    No related Items
paperclip

#34702647   2021/10/23 To Up

Improving Guideline Adherence in Urology.

Clinical practice guidelines (CPGs) distil an evidence base into recommendations. CPG adherence is associated with better patient outcomes. However, preparation and dissemination of CPGs are a costly task involving multiple skilled personnel. Furthermore, dissemination alone does not ensure CPG adherence. Reasons for nonadherence are often complex, but understanding practice variations and reasons for nonadherence is key to improving CPG adherence and harmonising clinically appropriate and cost-effective care.
Steven MacLennan, Eilidh Duncan, Ted A Skolarus, Monique J Roobol, Veeru Kasivisvanathan, Kevin Gallagher, Giorgio Gandaglia, Vasileios Sakalis, Emma Jane Smith, Karin Plass, Maria J Ribal, James N'Dow, Alberto Briganti

1450 related Products with: Improving Guideline Adherence in Urology.

100 μg50mg100 μg100.00 ug100 μg100 ml.10ug100 μg5 ready-to-use apoptosis 1000

Related Pathways

    No related Items
paperclip

#34701855   // To Up

The Radiosensitizing Effects of Enzalutamide on Glioblastoma.

To explore the radiosensitizing effects of enzalutamide (ENZ), an androgen receptor (AR) antagonist, on glioblastoma (GBM) in vitro and in vivo.
N Zhao, F Wang, S Wang, C Lin, C Zhang

1283 related Products with: The Radiosensitizing Effects of Enzalutamide on Glioblastoma.

1 6 ml Ready-to-use 500 Units10 μg 25 MG1 25 ml 1mg

Related Pathways